View Item 

Show simple item record

Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity
dc.contributor.authorHu, Yongjunen_US
dc.contributor.authorShen, Hongen_US
dc.contributor.authorKeep, Richard F.en_US
dc.contributor.authorSmith, David E.en_US
dc.date.accessioned2010-04-01T15:25:28Z
dc.date.available2010-04-01T15:25:28Z
dc.date.issued2007-12en_US
dc.identifier.citationHu, Yongjun; Shen, Hong; Keep, Richard F.; Smith, David E. (2007). "Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity." Journal of Neurochemistry 103(5): 2058-2065. <http://hdl.handle.net/2027.42/65903>en_US
dc.identifier.issn0022-3042en_US
dc.identifier.issn1471-4159en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/65903
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17854384&dopt=citationen_US
dc.format.extent196221 bytes
dc.format.extent3110 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 The Authors Journal Compilation 2007 International Society for Neurochemistryen_US
dc.subject.other5-aminolevulinic Aciden_US
dc.subject.otherBrainen_US
dc.subject.otherExpressionen_US
dc.subject.otherNeurotoxicityen_US
dc.subject.otherPeptide Transporter 2en_US
dc.titlePeptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicityen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Department of Pharmaceutical Sciences and Upjohn Center for Clinical Pharmacology, The University of Michigan, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationum† Departments of Neurosurgery and Physiology, The University of Michigan, Ann Arbor, Michigan, USAen_US
dc.identifier.pmid17854384en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/65903/1/j.1471-4159.2007.04905.x.pdf
dc.identifier.doi10.1111/j.1471-4159.2007.04905.xen_US
dc.identifier.sourceJournal of Neurochemistryen_US
dc.identifier.citedreferenceAdhikari A., Penatti C. A. A., Resende R. R., Ulrich H., Britto L. R. G. and Bechara E. J. H. ( 2006 ) 5-Aminolevulinate and 4, 5-dioxovalerate ions decrease GABA A receptor density in neuronal cells, synaptosomes and rat brain. Brain Res. 1093, 95 – 104.en_US
dc.identifier.citedreferenceAlbers J. W. and Fink J. K. ( 2004 ) Porphyric neuropathy. Muscle Nerve 30, 410 – 422.en_US
dc.identifier.citedreferenceAnderson K. E., Sassa S., Bishop D. F. and Desnick R. J. ( 2001 ) Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias, in The Metabolic & Molecular Bases of Inherited Disease ( Scriver C. R., Beaudet A. L., Sly W. S. and Valle D., eds ), pp. 2991 – 3062. McGraw-Hill, New York.en_US
dc.identifier.citedreferenceCapecchi M. R. ( 1994 ) Targeted gene replacement. Sci. Am. 270, 52 – 59.en_US
dc.identifier.citedreferenceDaniel H. and Kottra G. ( 2004 ) The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 447, 610 – 618.en_US
dc.identifier.citedreferenceDaniel H. and Rubio-Aliaga I. ( 2003 ) An update on renal peptide transporters. Am. J. Physiol. 284, F885 – F892.en_US
dc.identifier.citedreferenceDÖring F., Walter J., Will J., FÖcking M., Boll M., Amasheh S., Clauss W. and Daniel H. ( 1998 ) Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J. Clin. Invest. 101, 2761 – 2767.en_US
dc.identifier.citedreferenceEdwards S. R., Shanley B. C. and Reynoldson J. A. ( 1984 ) Neuropharmacology of delta-aminolaevulinic acid-I: effect of acute administration in rodents. Neuropharmacology 23, 477 – 481.en_US
dc.identifier.citedreferenceElmquist W. F. and Miller D. W. ( 2001 ) The use of transgenic mice in pharmacokinetic and pharmacodynamic studies. J. Pharm. Sci. 90, 422 – 435.en_US
dc.identifier.citedreferenceFrey I. M., Rubio-Aliaga I., Siewert A. et al. ( 2007 ) Profiling at mRNA, protein, and metabolite levels reveals alterations in renal amino acid handling and glutathione metabolism in kidney tissue of PEPT2 -/- mice. Physiol. Genomics 28, 301 – 310.en_US
dc.identifier.citedreferenceGorchein A. and Webber R. ( 1987 ) δ-Aminolevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects. Clin. Sci. 72, 103 – 112.en_US
dc.identifier.citedreferenceJonker J. W., Buitelaar M., Wagenaar E. et al. ( 2002 ) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl Acad. Sci. USA 99, 15649 – 15654.en_US
dc.identifier.citedreferenceKazemi H. and Johnson D. C. ( 1986 ) Regulation of cerebrospinal fluid acid-base balance. Physiol. Rev. 66, 953 – 1037.en_US
dc.identifier.citedreferenceKeep R. F. and Smith D. E. ( 2006 ) Oligopeptide transport at the blood-brain and blood-CSF barriers, in Handbook of Biologically Active Peptides ( Kastin A. J., ed ), pp. 1423 – 1428. Elsevier, Amsterdam, Holland.en_US
dc.identifier.citedreferenceKeep R. F., Si X., Shakui P., Ennis S. R. and Betz A. L. ( 1999 ) Effect of amiloride analogs on DOCA-salt-induced hypertension in rats. Am. J. Physiol. 276, H2215 – H2220.en_US
dc.identifier.citedreferenceKlaassen C. D. ( 2006 ) Heavy metals and heavy-metal antagonists, in Goodman & Gilman’s The Pharmacological Basis of Therapeutics ( Brunton L. L., Lazo J. S. and Parker K. L., eds ), pp. 1753 – 1775. McGraw-Hill, New York.en_US
dc.identifier.citedreferenceLindberg R. L. P., Martini R., Baumgartner M. et al. ( 1999 ) Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J. Clin. Invest. 103, 1127 – 1134.en_US
dc.identifier.citedreferenceNovotny A., Xiang J., Stummer W., Teuscher N. S., Smith D. E. and Keep R. F. ( 2000 ) Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J. Neurochem. 75, 321 – 328.en_US
dc.identifier.citedreferenceOcheltree S. M., Shen H., Hu Y., Xiang J., Keep R. F. and Smith D. E. ( 2004 ) Role of PEPT2 in the choroid plexus uptake of glycylsarcosine and 5-aminolevulininc acid: studies in wild-type and null mice. Pharm. Res. 21, 1680 – 1685.en_US
dc.identifier.citedreferenceOcheltree S. M., Shen H., Hu Y., Keep R. F. and Smith D. E. ( 2005 ) Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J. Pharmacol. Exp. Ther. 315, 240 – 247.en_US
dc.identifier.citedreferencePinsonneault J., Nielsen C. U. and SadÉe W. ( 2004 ) Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J. Pharmacol. Exp. Ther. 311, 1088 – 1096.en_US
dc.identifier.citedreferenceRubio-Aliaga I., Frey I., Boll M., Groneberg D. A., Eichinger H. M., Balling R. and Daniel H. ( 2003 ) Targeted disruption of the peptide transporter Pept2 gene in mice defined its physiological role in the kidney. Mol. Cell. Biol. 23, 3247 – 3252.en_US
dc.identifier.citedreferenceSchinkel A. H., Smit J. J. M., van Tellingen O. et al. ( 1994 ) Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491 – 502.en_US
dc.identifier.citedreferenceShen H., Smith D. E., Yang T., Huang Y. G., Schnermann J. B. and Brosius F. C. III ( 1999 ) Localization of PEPT1 and PEPT2 proton-couple oligopeptide transporter mRNA and protein in rat kidney. Am. J. Physiol. 276, F658 – F664.en_US
dc.identifier.citedreferenceShen H., Smith D. E., Keep R. F., Xiang J. and Brosius F. C. III ( 2003 ) Targeted disruption of the PEPT2 gene markedly reduces dipeptide uptake in choroid plexus. J. Biol. Chem. 278, 4786 – 4791.en_US
dc.identifier.citedreferenceShen H., Smith D. E., Keep R. F. and Brosius F. C. III ( 2004 ) Immunolocalization of the proton-coupled oligopeptide transporter PEPT2 in developing rat brain. Mol. Pharm. 1, 248 – 256.en_US
dc.identifier.citedreferenceShen H., Ocheltree S., Hu Y., Keep R. F. and Smith D. E. ( 2007 ) Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption and brain penetration in mice. Drug Metab. Dispos. 35, 1209 – 1216en_US
dc.identifier.citedreferenceShiogai T.., Nara I., Saruta K., Hara M. and Saito I ( 1999 ) Continuous monitoring of cerebrospinal fluid acid-base balance and oxygen metabolism in patients with severe head injury: pathophysiology and treatments for cerebral acidosis and ischemia. Acta Neurochir. Suppl. 75, 49 – 55.en_US
dc.identifier.citedreferenceSmith D. E., Johanson C. E. and Keep R. F. ( 2004 ) Peptide and peptide analog transport systems at the blood-CSF barrier. Adv. Drug Deliv. Rev. 56, 1765 – 1791.en_US
dc.identifier.citedreferenceTerada T., Irie M., Okuda M. and Inui K. ( 2004 ) Genetic variant Arg57His in human H+/peptide cotransporter 2 causes a complete loss of transport function. Biochem. Biophys. Res. Commun. 316, 416 – 420.en_US
dc.identifier.citedreferenceTeuscher N. S., Shu C., Xiang J., Keep R. F. and Smith D. E. ( 2004 ) Carnosine uptake in rat choroid plexus primary cell cultures and choroid plexus whole tissue from PEPT2 null mice. J. Neurochem. 89, 375 – 382.en_US
dc.identifier.citedreferenceWang L., Yan D., Gu Y., Sun L.-G. and Ruan D.-Y. ( 2005 ) Effects of extracellular δ-aminolaevulinic acid on sodium currents in acutely isolated rat hippocampal CA1 neurons. Eur. J. Neurosci. 22, 3122 – 3128.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1471-4159.2007.04905.x.pdf
Size:
191.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.